Form 4: Mural Oncology CMO Sells Shares for Tax Obligations

Mural Oncology's Chief Medical Officer, Vicki L. Goodman, sold 5,036 ordinary shares at $2.08 each to cover tax withholding obligations related to vested restricted stock units.

Summary

• Vicki L. Goodman, Chief Medical Officer of Mural Oncology plc, reported a sale of ordinary shares.
• A total of 5,036 ordinary shares were sold on November 10, 2025.
• The shares were sold at a price of $2.08 per share.
• The sale was automatic and non-discretionary, executed to satisfy tax withholding obligations arising from the vesting of restricted stock units.
• The transaction was conducted under a Rule 10b5-1 plan established on December 22, 2023.
• Following the transaction, Ms. Goodman beneficially owns 84,727 ordinary shares, which includes 71,509 unvested restricted stock units.

Sentiment

Score: 5

Explanation: Neutral. The transaction is a routine, non-discretionary sale for tax purposes related to RSU vesting, which is a common occurrence for executives and does not reflect a change in sentiment towards the company's prospects.

Positives

• The sale was non-discretionary and pre-planned under a Rule 10b5-1 plan, indicating it was not a market timing decision by the insider.
• The transaction is a routine event related to RSU vesting and tax obligations, not a signal of lack of confidence in the company.

Negatives

• A reduction in direct share ownership by a key executive, even if for tax purposes, slightly decreases their direct equity stake.

Future Outlook

NA

Industry Context

This is a routine insider transaction for tax purposes and does not provide specific insights into broader industry trends or competitive landscape for Mural Oncology plc.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes, not indicative of a change in company fundamentals or executive confidence.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of shares by a Chief Medical Officer to cover tax obligations upon RSU vesting. Such transactions are common and pre-planned under Rule 10b5-1, meaning they do not reflect a discretionary decision by the insider regarding the company's future prospects. Therefore, this specific filing does not provide new information that would warrant a change in investment recommendation; a 'hold' stance is maintained based on the lack of new fundamental insights.

Keywords

Mural Oncology, MURA, Form 4, Insider Trading, Stock Sale, Vicki L. Goodman, Chief Medical Officer, Restricted Stock Units, Tax Withholding, Rule 10b5-1